Moreover, patients with high expression of TET2 and KMT2D present a better prognostic outcome in contrast to patients with low expression of the counterparts (Fig. 6D), implying that combination analysis of TET2 and KMT2D harbors clinical potential for patients with HCC. The gene discussed is TET2; the disease is hepatocellular carcinoma.